Chancievan Thangaratnarajah

The paper identifies key chemical features of inhibitors binding to the human mitochondrial pyruvate carrier hetero-dimer and discovers new inhibitors with higher potency than existing ones.

The paper determines the crystal structure of the BMPR2 kinase domain and analyzes how disease-associated mutations affect its stability and potential for therapeutic intervention.